Commission Implementing Regulation (EU) 2026/702

Contents

THE EUROPEAN COMMISSION,Having regard to the Treaty on the Functioning of the European Union,Having regard to Regulation (EU) 2016/1036 of the European Parliament and of the Council of 8 June 2016 on protection against dumped imports from countries not members of the European Union^note, and in particular Article 9(1) thereof,Having regard to Regulation (EU) 2016/1037 of the European Parliament and of the Council of 8 June 2016 on protection against subsidised imports from countries not members of the European Union^note and in particular Article 14(1) thereof,Whereas:

(1)Certain imports of biodiesel originating in United States of America are subject to definitive anti-dumping and countervailing duties imposed by Commission Implementing Regulations (EU) 2021/1266^note and (EU) 2021/1267^note.

(2)Following two anti-circumvention investigations concluded in 2011, the measures were extended by Council Implementing Regulation (EU) No 444/2011^note to imports of biodiesel consigned from Canada and Council Implementing Regulation (EU) No 443/2011^note.

(3)On 17 March 2025 KD Pharma Canada Ltd informed the Commission that DSM Nutritional Products Canada Inc., (TARIC^note additional code C114), a company subject to an exemption of the individual anti-dumping duty rate of EUR 172,2 per tonne net, had changed its name to KD Pharma Canada Ltd and requested DSM Nutritional Products Canada Inc. to transfer its TARIC additional code C114 to the former.

(4)According to the information provided, it appeared that DSM Nutritional Products Canada Inc., continued to exist as a singular entity in its current form, under the same name.

(5)After carrying out an examination of the request, on 8 January 2026, the Commission informed KD Pharma Canada Ltd by letter of its intention to reject the request on the ground that the request did not constitute a case for a change of company name.

(6)The Commission rejected this request on the ground that only companies with clearly verified continuity in law, structure and operations can have their names updated in the Regulation.

(7)On 8 January 2026, the Commission disclosed its findings to KD Pharma Canada Ltd and invited the company to provide comments. No comments were received.

(8)The measures provided for in this Regulation are in accordance with the opinion of the Committee established by Article 15(1) of Regulation (EU) 2016/1036,

HAS ADOPTED THIS REGULATION: